Fulgent Genetics Inc (FLGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fulgent Genetics Inc (FLGT) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($11.11 Million) by net assets ($1.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fulgent Genetics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Fulgent Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Fulgent Genetics Inc total liabilities for a breakdown of total debt and financial obligations.
Fulgent Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulgent Genetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A
SHE:301290
|
N/A |
|
Ependion AB
ST:EPEN
|
0.080x |
|
Weave Communications Inc
NYSE:WEAV
|
0.077x |
|
Hillstone Networks Co Ltd
SHG:688030
|
-0.034x |
|
Guangdong Kitech New Material Holding Co.Ltd.
SHE:300995
|
N/A |
|
Caledonia Mining Corporation
NYSE MKT:CMCL
|
0.050x |
|
Shanghai Karon Eco-Valve Manufacturing Co. Ltd.
SHE:301151
|
0.168x |
|
Jiangsu Tianmu Lake Tourism Co Ltd
SHG:603136
|
0.043x |
Annual Cash Flow Conversion Efficiency for Fulgent Genetics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Fulgent Genetics Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Fulgent Genetics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.13 Billion | $21.06 Million | 0.019x | -21.72% |
| 2023-12-31 | $1.13 Billion | $27.00 Million | 0.024x | -88.07% |
| 2022-12-31 | $1.27 Billion | $253.52 Million | 0.200x | -56.78% |
| 2021-12-31 | $1.17 Billion | $538.58 Million | 0.462x | +87.04% |
| 2020-12-31 | $569.39 Million | $140.63 Million | 0.247x | +270.57% |
| 2019-12-31 | $82.78 Million | $5.52 Million | 0.067x | +616.11% |
| 2018-12-31 | $52.27 Million | $-675.00K | -0.013x | -152.42% |
| 2017-12-31 | $54.03 Million | $1.33 Million | 0.025x | -69.53% |
| 2016-12-31 | $54.48 Million | $4.41 Million | 0.081x | +142.94% |
| 2015-12-31 | $5.15 Million | $-969.00K | -0.188x | +92.79% |
| 2014-12-31 | $1.68 Million | $-4.40 Million | -2.611x | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more